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Abstract 
We performed a meta-analysis of data on the effectiveness and safety of apixaban compared 
with other oral anticoagulants (OACs, warfarin or rivaroxaban or dabigatran or edoxaban) for 
stroke prevention in atrial fibrillation (AF) in different settings of randomized controlled trials 
(RCTs), real-world studies, and radiofrequency ablation (RFA).  30 studies were searched in 
PubMed, the Cochrane Library and Clinicaltrials.gov databases reporting comparative 
effectiveness and safety of apixaban with warfarin (n=23), rivaroxaban (n=12) or dabigatran 
(n=13) or edoxaban (2) for stroke prevention in AF. In real-world estimates, apixaban was 
similar to warfarin for the prevention of stroke or systematic thromboembolism (Stroke/TE) 
(HR: 0.93, 95% CI: 0.71-1.14, I2=82.9%, N=7), and safer than warfarin in the risks of major 
bleeding, (HR: 0.62, 95% CI: 0.54-0.70, I2=18.7%, N=9) in AF patients.  The risk of stroke/TE 
with apixaban was similar to rivaroxaban, dabigatran and edoxaban in the settings of 
real-world studies and RFA.  Major bleeding with apixaban was generally lower than 
rivaroxaban(RR: 0.45, 95% CI: 0.38-0.53, I2=0%, N=5) and similar to dabigatran in real-world 
studies (RR: 1.44, 95% CI: 0.33-6.30, I2=97.7%, N=5), but similar to rivaroxaban, dabigatran 
and edoxaban in RFA. In conclusion, our meta-analysis provides a comprehensive estimate of 
the effectiveness and safety of apixaban compared with other OACs (warfarin, rivaroxaban, 
dabigatran, and edoxaban) in AF patients in different settings of RCT, real-world studies, and 
RFA.    
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Introduction 
In recent years, the development of non-vitamin-K antagonist oral anticoagulants (NOACs), 
including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, 
apixaban and edoxaban) have increased therapeutic options for anticoagulation and could 
potentially overcome many drawbacks of warfarin.1 Indeed, the NOACs provide a more 
convenient, and even more effective and safer alternative approach to warfarin in clinical 
practice 2,3 Further direct comparison assessments are therefore warranted for NOACs, 
especially apixaban, which became available much later than rivaroxaban and dabigatran. 
This meta-analysis was performed to focus on the oral Factor Xa inhibitor apixaban, with 
direct comparison data on the effectiveness and safety of the NOACs compared with warfarin, 
rivaroxaban, dabigatran or edoxaban for stroke prevention in AF in different settings such as 
RCTs, real-world studies, and radiofrequency ablation (RFA). 
 
Methods 
We followed the preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) and the reporting Meta-analyses of Observational Studies in Epidemiology (MOOSE) 
when performing this meta-analysis.4,5 
    A comprehensive search of PubMed, the Cochrane Library and Clinicaltrials.gov 
databases were performed by 2 independent reviewers (Y. B. and X-B. S.) using the following 
items “atrial fibrillation” OR “AF” AND “apixaban” OR “rivaroxaban” OR “dabigatran” OR 
“edoxaban” OR “warfarin” OR "NOAC" OR"DOAC" AND "human" on 20th July, 2016, and 
updated on 17th April, 2017. Any discrepancies were resolved by re-evaluation to reach 
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consensus. 
Studies that investigated the comparison between apixaban and the other OACs 
(warfarin, rivaroxaban or dabigatran or edoxaban) were included in the meta-analysis. Other 
inclusion criteria are as follows: (i) OACs used for stroke prevention in AF patients; (ii).Clearly 
defined outcomes of effectiveness or safety; and (iii). Studies published in English. We 
defined the effectiveness and safety outcomes based on the original papers. Outcomes of 
effectiveness included IS and Stroke/TE. Outcomes of safety were defined as major bleeding, 
intracranial hemorrhage (ICH) and gastrointestinal bleeding (GIB). For studies that did not 
report combined stroke and TE, separate IS, stroke or TE was used instead for meta-analysis.  
No restrictions on study size were defined in our analysis. Abstracts, editorials, case-reports, 
reviews and case series were also excluded. Studies using duplicate data were excluded 
unless additional information was provided. 
The analysis was conducted using STATA, version 12.0 (Stata Corp.).  Relative risks (RR) 
with 95% confidence intervals (95% CI) were mainly used to measure the effect sizes in our 
study, but we used adjusted hazard ratios for the comparisons of apixaban and warfarin in 
real-world studies. First, we used a fixed model, and then a random effects model if there 
was heterogeneity according to I2 index .6  Values of ≤ 25%, 25% to 50%, and ≥50% were 
defined as low, moderate and high degrees of heterogeneity, respectively.  Begg’s 
correlation test and Egger’s regression test were used to assess publication bias and Begg’s 
correlation was used where study numbers were < 3.7,8  P<0.05 was taken as statistically 
significant.  
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Results 
A total of 1936 studies were initially identified. After screening titles and abstracts, we 
excluded 1863 papers and 73 remained for detailed evaluation. Of these, 42 were excluded 
as they did not meet the inclusion criteria (7 reviews and meta-analysis; 7 papers without 
outcomes of OACs; 9 papers without separate information on apixaban or rivaroxaban or 
dabigatran or edoxaban; 12 studies with duplicate data, 1 on the setting of direct current 
cardioversion and 7 with mixed diseases except for AF). Finally, 30 studies were included,9-39 
11 of which were studies on specific settings of RFA 9,11-20. The selection process is shown in 
Supplementary Figure I.  
Baseline characteristics categorized by different settings are summarized in Table 1, 2 
and 3. Extracted data of risk of stroke and TE, and major bleeding comparing apixaban with 
warfarin, rivaroxaban, dabigatran and edoxaban are shown in Supplementary Tables I- VIII. 
When compared to warfarin, we found similar effectiveness of apixaban in stroke/TE 
prevention in the settings of real-world studies (HR: 0.93, 0.71-1.14, I2=82.9%, N=7) (Figure 
1a), and RFA (RR: 1.26, 0.75-2.11, I2=0.0%, N=9), but superiority in RCTs (RR: 0.78, 95% CI: 
0.65-0.93, I2=19.6%, N=2) (Figure 2a).  
Compared to warfarin, apixaban was associated with similar risk of major bleeding in 
the setting of RFA (RR: 1.12, 0.52-2.42, I2=0.0%, N=10) (Figure 2b), but lower risks in the 
settings of real-world studies (HR: 0.62, 0.54-0.70, I2=66.9%, N=9) (Figure 1b) and RCTs (RR: 
0.70, 0.61-0.81, I2=0.0%, N=2). (Figure 2b). 
We performed subgroup analyses on IS, ICH and GIB in real-world studies using adjusted 
HRs. Apixaban had a similar risk of IS compared with warfarin in AF patients (HR:  0.95, 95% 
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CI: 0.73-1.17, I2=80.3%, N=7), but was associated with reduced risk of ICH (HR: 0.51, 
0.42-0.60, I2=51.4%, N=7) and GIB (HR: 0.60, 0.54-0.67, I2=32.8%, N=4) compared with 
warfarin (Supplementary Figure II). 
Apixaban had similar effectiveness for stroke/TE prevention when compared to 
rivaroxaban (RR: 1.46, 0.90-2.36, I2=0.0%, N=5) or dabigatran (RR: 0.89, 0.51-1.57, I2=0.0%, 
N=3) or edoxaban  (RR: 0.92, 0.44-1.91, I2=0.0%, N=2)  in the settings of RFA (Figure 3a, 
Supplementary Figure III a and Figure IV a), or compared to rivaroxaban (HR:1.16, 0.84-1.60, 
N=1) and dabigatran in the real-world studies (Supplementary Figure III a) (HR: 0.42, 
0.04-5.02, I2=66.9%, N=2).  A lower risk of major bleeding was seen in real-world studies 
when apixaban was compared to rivaroxaban (RR: 0.45, 0.38-0.53, I2=0.0%, N=5), but 
non-significantly different in the real-world studies when apixaban was compared to 
dabigatran (RR: 1.44, 0.33-6.30, I2=97.7%, N=5) (Figure 3b and Supplementary Figure III b) 
or in RFA when compared to rivaroxaban , dabigatran or edoxaban (Figure 3b, 
Supplementary Figure III b and Supplementary Figure IV b).  
Apixaban was associated with similar risk of IS, ICH, and GIB compared with rivaroxaban 
or dabigatran in AF patients, when analyses were performed in real-world studies 
(Supplementary Figure V). 
No apparent publication bias was seen for all the meta-analyses performed 
(Supplementary Table IX). 
 
Discussion 
In this meta-analysis, our principal findings are as follows: (i) apixaban was associated 
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with similar effectiveness of Stroke/TE prevention compared with warfarin, dabigatran, 
rivaroxaban and edoxaban in real-world studies, and RFA; (ii) apixaban had similar safety to 
warfarin, rivaroxaban ,dabigatran and edoxaban for major bleeding in the setting of RFA, but 
was safer than warfarin in RCTs and real-world studies; (iii) apixaban was safer than 
rivaroxaban in real-world studies, and had similar safety compared to dabigatran; and (iv). 
apixaban had similar risk of ischemic stroke prevention compared to other OACs (warfarin, 
rivaroxaban and dabiagatran), but lower risk of ICH and GIB compared with warfarin in 
real-world studies. 
This meta-analysis mainly focuses on the effectiveness and safety of apixaban, when 
compared with warfarin and other NOACs in AF patients based on different settings, 
including real-world studies, and RFA. The results are partially discordant from meta-analysis 
of the RCTs comparing apixaban with warfarin for the risk of stroke/TE in AF patients, which 
found the rate of Stroke/TE being 22% lower in apixaban compared with warfarin.2,3 
Confounding by indication is a known limitation in observational studies, and could partly 
explain why a similar risk of Stroke/TE with apixaban vs. warfarin was seen in most real-world 
studies.27 Also, different diagnosis codes between the observational studies and RCTs may 
partially explain some of the discordant findings.  
Hemorrhagic stroke was part of the composite of (all) stroke/TE in RCTs,21 but not 
included in some observational studies in which ischemic stroke solely was evaluated based 
on cerebral infarction.24,25 This assumption is supported by the subgroup analyses showing 
similar risk of ischemic stroke in comparisons of apixaban with warfarin in real-world studies 
(Supplementary Figure II). 
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The effectiveness of Stroke/TE prevention in apixaban was similar to rivaroxaban or 
dabigatran or edoxaban in the settings of real-world studies, and RFA, consistent with 
previous indirect comparisons.40 However, apixaban was superior to rivaroxaban in 
real-world studies, but similar to dabigatran in terms of safety, that is, major bleeding. No 
significant differences were evident between apixaban and other NOACs (rivaroxaban or 
dabigatran) with respect to other outcomes in everyday clinical practice. This might reflect 
the smaller number of events due to relatively fewer studies focused on the apixaban 
comparisons. 
Consistent with previous meta-analysis of NOACs for RFA,41,42 apixaban showed 
comparative effectiveness and safety with warfarin. Apixaban was non-inferior to rivaroxaban, 
dabigatran, and edoxaban when studies were performed on the terms of stroke/TE and 
major bleeding within NOACs in patients receiving RFA treatment. Further studies with larger 
populations and more high-quality follow-up are needed, and 1 prospective RCT is ongoing.43 
This analysis should be interpreted with caution due to various limitations, some of 
which were inherent with any meta-analysis. Owing to the small sample size, there may be 
lower power in some included studies, hence the difficulty in drawing any firm conclusions 
on the safety outcomes of GIB and ICB of apixaban compared to other NOACs (rivaroxaban 
and dabigatran). Second, as apixaban was a relatively new NOAC and the follow-up period 
was usually shorter than other OACs, hence the ‘peak’ of adverse effects may not be reached 
in some observational studies.23,30   Third, some events were crudely estimated because of 
no access to the original data, but we estimated the results using the adjusted HR for 
comparison of apixaban vs. warfarin in real-world studies. The lack of publication bias 
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increases the reliability of the pooled estimate. Despite these limitations, this meta-analysis 
includes all relevant studies providing head-to-head comparisons of apixaban with other 
OACs.  
Our meta-analysis provides a comprehensive estimate of the effectiveness and safety of 
apixaban compared with other OACs (warfarin, rivaroxaban, dabigatran and edoxaban) in AF 
patients.    
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Figure 1.Risk of Stroke/TE (a) and major bleeding (b) in comparison of Apixaban versus 
Warfarin in AF patients in real-world studies; AF, atrial fibrillation; IS, ischemic stroke; TE, 
systematic thromboembolism. 
 
Figure 2. Risk of Stroke/TE (a) and major bleeding (b) in comparison of Apixaban versus 
Warfarin in AF patients with different settings; PAE, peripheral arterial embolism; RCT, 
randomized controlled trials; RFA, radiofrequency ablation; TIA, transient ischemic attack. a, 
Outcome refers to stroke/TE if not stated; b, Outcome refers to major bleeding if not stated. 
Other abbreviations see Figure 1. 
 
Figure 3. Risk of Stroke/TE (a) and major bleeding (b) in comparison of Apixaban versus 
Rivaroxaban in AF patients with different settings; PE, pulmonary embolism; a, Outcome 
refers to stroke/TE if not stated; b, Outcome refers to major bleeding if not stated. 
Other abbreviations see Figure 1 and 2. 
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Table 1.  Baseline characteristics of studies comparing apixaban versus warfarin 
Author, year Region Period  Study design Cohort (Number) Low Dose (%) Follow-up 
Apixaban Warfarin Apixaban  
Coleman,201735 Germany 2013- 2014 Retrospective 937 7040 33.2 1 y 
Hohnloser,201736 Germany 2013- 2015 Retrospective 3,633 16,179 39 0.6-0.8 y 
Lamberts,201737 Denmark - 2015 Registry 7,963 24,230 – 1.1 y 
Li,201738 US 2013- 2015 Retrospective 38,470 38,470 17.1 0.5y 
Nielsen,201739 Denmark 2011- 2016 Cohort 4,400 38,893 100 1 y 
Lip,201623 US 2013- 2014 Retrospective  7,438 15,461 13.5 0.4 y 
Larsen, 201625 Denmark 2011- 2015 Cohort 6,349 35,436 0 1.9y 
Coleman,201624 US 2012- 2014 Retrospective 18,591 26,083 15.5 – 
Halvorsen,201626 Norway 2013- 2015 Registry 6,506 11,427 29.2 0.4 y 
Yao,201628 US 2010- 2015 Retrospective 7,698 85,869 18.1 0.5y; 
Staerk,201627 Denmark 2011-2015 Registry 6,899 18,094 36.9 2y 
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Granger,201121 Multi-center 2006- 2010 RCT 9120 9081 4.6 1.8y 
Ogawa,201122 Japan – RCT 148 74 50 0.25y 
RCT, randomized controlled trials; NOACs, non-vitamin-K antagonist anticoagulants ; –,Not available. 
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Table 2.   Baseline characteristics of studies comparing apixaban versus dabigatran or apixaban versus rivaroxaban 
Author, year Region Period  Study design Cohort (Number) Low dose (%) Follow-up 
Apixaba
n 
Dabigatra
n 
Rivaroxaba
n 
Apixaba
n 
Dabigatra
n  
Rivaroxaba
n 
Lip,201623 US 2013- 
2014 
Retrospectiv
e  
7,438 4,661 17,801 13.5 10.6 19.6 0.37-0.5y 
Al-Khalili,201630 Swede
n 
2011- 
2014 
Retrospectiv
e 
251 233 282 16.0 36.0 18.0 0.95-1.18
y 
Noseworthy,2016
29 
US 2010- 
2015 
Retrospectiv
e 
6,542 6,542 – 18.1 13.0 – – 
Noseworthy,2016
29 
US 2010- 
2015 
Retrospectiv
e  
6,565 – 6,565 18.3 – 28.7 – 
Deitelzweig,20163
4 
US 2012- 
2014 
Retrospectiv
e  
4,138 32,838 37,754 – – – 0.08y 
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Khan,201631 US 2011- 
2013 
Retrospectiv
e 
14 52 76 – – – 2.56 y 
Pasca,201633 Italy 2013- 
2015 
Prospective 66 23 54 62.1 69.6 44.5 0.8y 
Lee,201532 UK 2013- 
2014 
Retrospectiv
e 
53 53 127 – – – 0.92y 
*Prospective cohort study, others Retrospective cohort studies. –,Not available. 
 
 
Page 21 of 23
 22 
Table 3. Baseline characteristics of studies on oral anticoagulants used in radiofrequency ablation 
Author, year Region Period Study design Cohort (Number) Periprocedural Oral Anticogulants  
Apixaba
n 
Warfari
n 
Rivaroxaba
n 
Dabigatra
n 
Uninterrupted Interrupte
d 
Yoshimura,201620 Japan 2013- 
2014 
prospective 50 69 55 – warfarin, 
rivaroxaban  
apixaban 
*Nakamura,20161
7 
Japan 2014- 
2015 
Retrospectiv
e 
87 46 89 47 warfarin NOAC 
*Okishige,201618 Japan – Retrospectiv
e 
30 19 81 66 warfarin NOACs 
Hansen,201612 Sweden 2011- 
2014 
Prospective 25 – 38 171 – NOACs 
Koektuerk,201614 Germany 2012- 
2015 
Retrospectiv
e 
18 150 193 48 – NOACs 
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Kuwahara,201615 Japan – RCT 100 100 – – warfarin ,apixaban – 
Di Biase,201511 US, 
Europe 
2013- 
2014 
Prospective  200 200 – – warfarin, apixaban – 
Rillig,201519 Germany 2013- 
2014 
– 80 120 193 51 warfarin – 
Nagao,201416 Japan 2013- 
2014 
Retrospectiv
e 
105 237 – – warfarin, apixaban – 
Kaess,201413 Germany - 2014 Matched  105 210 – – warfarin , apixaban – 
Armbruster,20149 US 2012- 
2013 
Retrospectiv
e  
17 173 61 123 warfarin – 
RCT, randomized controlled trials; NOACs, non-vitamin-K antagonist anticoagulants; 
*The numbers of edoxaban are 17 and 61 in Nakamura,201617 and Okishige,201618, separately. 
–, Not available. 
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